Novalead's Innovative DFU Gel Launch

Novalead Pharma, a drug repurposing venture, is set to launch its novel diabetes foot ulcer (DFU) gel next month. The 15-year-old venture received greenlight from the Indian drug regulator for its topical gel formulation of Esmolol hydrochloride, an existing drug approved in several countries for cardiac conditions. The "repurposed" drug is not a "line extension" of an existing product but a novel, "non-obvious" use of an existing drug from a different company. Novalead is in advanced discussions with a pharmaceutical company to take the product to a wider audience. The drug has undergone Phase I and II trials overseas and India through contract research organizations, while Phase III trials were conducted in India.

 Novalead has submitted to the US FDA for Phase III trials, with an additional $65 million needed for Europe and the US. The drug's approval is based on positive results in a randomized, double blind Phase 3 clinical trial, with funding from high net worth individuals, family trusts, private equity, and founders.